https://www.pharmaceutical-technology.com/data-insights/df-6002-dragonfly-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
transitional cell carcinomadfdragonflytherapeuticsurothelial
https://pubmed.ncbi.nlm.nih.gov/22903481/
There is an association between decreased E-Cadherin immunoexpression and tumor recurrence in low-grade and non-muscle invasive transitional cell carcinoma of...
transitional cellcadherinexpressionprognosticfactor
https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-282554&utm_campaign=recommended-articles-pi
VAXINIA is under clinical development by Imugene and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer).
transitional cell cancerimugeneurothelial